JOURNAL ARTICLE

[Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis]

Filippo Mocciaro, Ambrogio Orlando, Daniela Scimeca, Mario Cottone
Recenti Progressi in Medicina 2007, 98 (11): 560-4
18044405
Tumor Necrosis Factor alpha plays a main role in ulcerative colitis. Thirteen male and 8 female affected by moderate to severe steroid-dependent or refractory-severe ulcerative colitis were treated with 5 mg/kg of infliximab (Remicade). At 12 week efficacy, steroid-sparing, colectomy and side effects were evaluated. In steroid-dependent group (13 patients): 8 patients had a clinical benefit (7 obtained a clinical remission, 54%), 8 (61.5%) discontinued steroids, 1 patient underwent surgery. In steroid-severe refractory group (8 patients): 3 patients (37.5%) had a clinical remission, 2 (25%) had a clinical response and 3 (37.5%) underwent colectomy. One mild infusion reaction and one adverse event (itch) were observed. Infliximab is an effective and safe therapy in patients with moderate to severe steroid dependent and refractory ulcerative colitis.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
18044405
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"